Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cangrelor
Drug ID BADD_D00348
Description Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
Indications and Usage For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Marketing Status Prescription
ATC Code B01AC25
DrugBank ID DB06441
KEGG ID D03359
MeSH ID C117446
PubChem ID 9854012
NDC Product Code 10122-620; 68225-062; 50137-3312
Synonyms cangrelor | N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid) | cangrelor tetrasodium | AR C69931MX | AR-C69931MX | Kengreal
Chemical Information
Molecular Formula C17H25Cl2F3N5O12P3S2
CAS Registry Number 163706-06-7
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute kidney injuryUromodulinP07911Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction24.06.03.006;
Anaphylactic shock24.06.02.004; Available
Angioedema23.04.01.001; Available
Bradycardia02.03.02.0020.000371%Not Available
Cardiac arrest02.03.04.0010.000145%
Gastric haemorrhage24.07.02.007;
Haemorrhage intracranial24.07.04.003;
Myocardial infarction24.04.04.009;
Pulmonary haemorrhage24.07.01.016;
Pulmonary oedema02.05.02.003;
Ventricular fibrillation02.03.04.0080.000371%
Haemorrhage24.07.01.0020.000556%Not Available
Renal impairment20.01.03.010--Not Available
Vascular stent thrombosis24.04.02.023; Available
Apparent life threatening event22.11.02.001;; Available
The 1th Page    1    Total 1 Pages